Halozyme Therapeutics, Inc. (HALO) is a publicly traded Healthcare sector company. As of July 21, 2026, HALO trades at $77.57 with a market cap of $9.23B and a P/E ratio of 26.27. HALO moved +0.52% today. Year to date, HALO is +13.87%; over the trailing twelve months it is +36.56%. Its 52-week range spans $46.26 to $82.26. Analyst consensus is buy with an average price target of $81.00. Rallies surfaces HALO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
6 analysts cover HALO: 0 strong buy, 3 buy, 2 hold, 1 sell, and 0 strong sell. The consensus rating is buy. The average price target is $81.00.
| Metric | Value |
|---|---|
| Price | $77.57 |
| Market Cap | $9.23B |
| P/E Ratio | 26.27 |
| EPS | $2.96 |
| Dividend Yield | 0.00% |
| 52-Week High | $82.26 |
| 52-Week Low | $46.26 |
| Volume | 44.04K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.51B |
| Net Income | $348.84M |
| Gross Margin | 82.79% |
6 analysts cover HALO: 0 strong buy, 3 buy, 2 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $81.00.